Yun-Jung Choi Selected Research

Biliary Liver Cirrhosis (Primary Biliary Cirrhosis)

2/2024	A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.
12/2023	Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis.
10/2023	Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis.
1/2023	Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.
1/2022	A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis.
1/2022	Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis.
10/2017	Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yun-Jung Choi Research Topics

Disease

15	Neoplasms (Cancer) 03/2018 - 08/2002
7	Biliary Liver Cirrhosis (Primary Biliary Cirrhosis) 02/2024 - 10/2017
7	Ovarian Neoplasms (Ovarian Cancer) 03/2018 - 01/2015
6	Pruritus (Itching) 02/2024 - 10/2017
4	Inflammation (Inflammations) 11/2023 - 05/2005
3	Wounds and Injuries (Trauma) 01/2023 - 01/2015
3	Mitochondrial Diseases (Mitochondrial Disease) 03/2018 - 01/2015
3	Gout 01/2018 - 01/2016
2	Communicable Diseases (Infectious Diseases) 04/2024 - 04/2018
2	Non-alcoholic Fatty Liver Disease 11/2023 - 01/2017
2	Cholestasis 10/2023 - 01/2022
2	Rheumatoid Arthritis 01/2018 - 01/2018
2	Weight Loss (Weight Reduction) 01/2017 - 01/2015
2	Dyslipidemias (Dyslipidemia) 01/2017 - 02/2012
2	Lung Neoplasms (Lung Cancer) 02/2016 - 09/2012
2	Carcinoma (Carcinomatosis) 02/2016 - 10/2006
2	Overweight 02/2012 - 09/2011
1	Infections 04/2024
1	Skin Diseases (Skin Disease) 12/2023
1	Liver Cirrhosis (Hepatic Cirrhosis) 11/2023
1	Liver Diseases (Liver Disease) 11/2023
1	Fibrosis (Cirrhosis) 11/2023
1	Alcoholic Fatty Liver 10/2023
1	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 01/2023
1	Pain (Aches) 12/2022
1	Postoperative Pain 12/2022
1	Burns 02/2022
1	Fatigue 01/2022
1	Disease Progression 01/2022
1	Genomic Instability 01/2020
1	Infertility (Sterility) 01/2019
1	Endometritis 04/2018
1	Hemophilia A (Haemophilia) 01/2018
1	Bone Resorption 01/2018
1	Joint Diseases (Joint Disease) 01/2018
1	Arthritis (Polyarthritis) 01/2018
1	Thromboembolism 01/2018
1	Spasm (Spasms) 10/2017
1	Dyspepsia (Indigestion) 10/2017
1	Dizziness (Lightheadedness) 10/2017
1	Nausea 10/2017
1	Myalgia 10/2017
1	Teratoma (Teratoid Tumor) 09/2017
1	Myocardial Infarction 01/2017
1	Body Weight (Weight, Body) 01/2017

Drug/Important Bio-Agent (IBA)

9	seladelparIBA 02/2024 - 01/2017
7	SilverIBA 04/2018 - 01/2014
6	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2024 - 02/2012
3	PPAR deltaIBA 12/2023 - 01/2017
3	Ursodeoxycholic Acid (Urso)FDA LinkGeneric 01/2023 - 10/2017
3	MicroRNAs (MicroRNA)IBA 01/2019 - 12/2016
3	Anti-Bacterial Agents (Antibiotics)IBA 04/2018 - 01/2015
3	graphene oxideIBA 03/2018 - 01/2015
3	Reactive Oxygen Species (Oxygen Radicals)IBA 03/2018 - 01/2015
3	arhalofenateIBA 01/2018 - 01/2016
3	(2- methyl- 4- (5- methyl- 2- (4- trifluoromethyl- phenyl)- 2H- (1,2,3)triazol- 4- ylmethylsulfanyl)phenoxy)acetic acidIBA 01/2017 - 09/2011
2	Alkaline PhosphataseIBA 02/2024 - 01/2022
2	Bile Acids and Salts (Bile Acids)IBA 12/2023 - 01/2022
2	Biomarkers (Surrogate Marker)IBA 10/2023 - 01/2022
2	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 03/2018 - 01/2015
2	Atorvastatin (Lipitor)FDA Link 01/2018 - 09/2011
2	Allopurinol (Remid)FDA LinkGeneric 01/2018 - 01/2016
2	LipidsIBA 01/2017 - 09/2011
2	Glucose (Dextrose)FDA LinkGeneric 01/2017 - 01/2015
2	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2017 - 01/2017
2	Uric Acid (Urate)IBA 01/2017 - 01/2016
2	Proteins (Proteins, Gene)FDA Link 02/2016 - 05/2005
2	Caspase 3 (Caspase-3)IBA 01/2015 - 08/2002
2	Annexin A5IBA 01/2015 - 04/2007
1	selonsertibIBA 01/2024
1	CytokinesIBA 12/2023
1	AntipruriticsIBA 12/2023
1	Messenger RNA (mRNA)IBA 11/2023
1	Hydroxyproline (4 Hydroxyproline)IBA 11/2023
1	CollagenIBA 11/2023
1	Liraglutide FDA Link 11/2023
1	Prednisolone (Predate)FDA LinkGeneric 10/2023
1	Histones (Histone)IBA 01/2020
1	Lysine (L-Lysine)FDA Link 01/2020
1	salinomycinIBA 03/2018
1	PhycoerythrinIBA 03/2018
1	Factor VIII (Coagulation Factor VIII)IBA 01/2018
1	LigandsIBA 01/2018
1	EpitopesIBA 01/2018
1	Antigen-Antibody Complex (Immune Complex)IBA 01/2018
1	Tumor Necrosis Factor InhibitorsIBA 01/2018
1	CD40 Ligand (CD40L)IBA 01/2018
1	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 01/2018
1	Macrophage Colony-Stimulating FactorIBA 01/2018
1	PerforinIBA 09/2017
1	Ribosomal Proteins (Ribosomal Protein)IBA 01/2017

Therapy/Procedure

14	Therapeutics 01/2024 - 04/2009
5	Drug Therapy (Chemotherapy) 01/2017 - 01/2015
1	Personal Protective Equipment 04/2024
1	Complementary Therapies (Alternative Medicine) 11/2023
1	Neurofeedback 01/2023
1	Nursing Care 12/2022
1	Local Anesthesia 12/2022
1	Emergency Treatment 02/2022
1	Ligation 01/2018